Loss of Nuclear Expression of the P33(ING1b) Inhibitor of Growth Protein in Childhood Acute Lymphoblastic Leukaemia

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2002 Jul 31

PMID 12147653

Citations 15

Authors

G S Nouman

J J Anderson

K M Wood

J Lunec

A G Hall

M M Reid

B Angus

Affiliations

Soon will be listed here.

Abstract

Background/aims: p33(ING1b) is a tumour suppressor protein involved in growth control and apoptosis. Suppression of p33(ING1b) expression is associated with the loss of cellular growth control and immortalisation, whereas its overexpression causes cell cycle arrest. Moreover, normal p33(ING1b) expression is essential for optimal function of p53. Acute lymphoblastic leukaemia (ALL) is the most common malignancy of childhood, accounting for one third of all childhood malignancies. A variety of cytogenetic abnormalities have been described but there is no single abnormality common to all cases. Deregulation of the TP53 pathway is a common genetic abnormality in human malignancies. However, TP53 mutations are uncommon in ALL. It is possible that alternative mechanisms of regulation of the TP53 apoptosis pathway, such as modulation of p33(ING1b) expression, may be important in ALL. The aim of this study was to assess the expression of p33(ING1b) in childhood ALL.

Methods: One hundred and forty five patients with childhood ALL were investigated in this immunohistochemical study of the expression of p33(ING1b).

Results: Loss of nuclear expression of p33(ING1b) was seen in 78% of cases. This was associated with increased cytoplasmic expression of the protein. Kaplan Meier survival analysis demonstrated a trend towards a better prognosis for patients with tumours that had lost nuclear p33(ING1b).

Conclusion: These results suggest that the loss of nuclear p33(ING1b) expression may be an important molecular event in the pathogenesis of childhood ALL.

Citing Articles

iWhale: a computational pipeline based on Docker and SCons for detection and annotation of somatic variants in cancer WES data.

Binatti A, Bresolin S, Bortoluzzi S, Coppe A Brief Bioinform. 2020; 22(3).

PMID: 32436933 PMC: 8557746. DOI: 10.1093/bib/bbaa065.

Ectopic expression of p33 suppresses proliferation and induces apoptosis in colonic adenocarcinoma cells.

Jia A, Lv Y, Guo X, Ren L, Qin J Oncol Lett. 2015; 10(3):1517-1522.

PMID: 26622701 PMC: 4533300. DOI: 10.3892/ol.2015.3385.

A novel tumor suppressor gene in basal cell carcinoma: inhibition of growth factor-2.

Temel M, Turkmen A, Dokuyucu R, Cevik C, Oztuzcu S, Cengiz B Tumour Biol. 2015; 36(6):4611-6.

PMID: 25613071 DOI: 10.1007/s13277-015-3108-9.

Src regulates the activity of the ING1 tumor suppressor.

Yu L, Thakur S, Leong-Quong R, Suzuki K, Pang A, Bjorge J PLoS One. 2013; 8(4):e60943.

PMID: 23585863 PMC: 3621671. DOI: 10.1371/journal.pone.0060943.

Cytoplasmic expression of p33(ING1b) is correlated with tumorigenesis and progression of human esophageal squamous cell carcinoma.

Zhu Z, Yan B, Zhang Y, Yang Y, Wang Z, Zhang H Oncol Lett. 2012; 5(1):161-166.

PMID: 23255913 PMC: 3525348. DOI: 10.3892/ol.2012.983.

References

Sarela A, Farmery S, Markham A, Guillou P . The candidate tumour suppressor gene, ING1, is retained in colorectal carcinomas. Eur J Cancer. 2000; 35(8):1264-7. DOI: 10.1016/s0959-8049(99)00104-5. View

Coustan-Smith E, Behm F, Sanchez J, Boyett J, Hancock M, Raimondi S . Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998; 351(9102):550-4. DOI: 10.1016/S0140-6736(97)10295-1. View

Kersey J . Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997; 90(11):4243-51. View

Seiter K, Feldman E, Sreekantaiah C, POZZUOLI M, Weisberger J, Liu D . Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia. 2001; 15(6):963-70. DOI: 10.1038/sj.leu.2402122. View

Garkavtsev I, Hull C, Riabowol K . Molecular aspects of the relationship between cancer and aging: tumor suppressor activity during cellular senescence. Exp Gerontol. 1998; 33(1-2):81-94. DOI: 10.1016/s0531-5565(97)00086-7. View

Sanchez-Cespedes M, Okami K, Cairns P, Sidransky D . Molecular analysis of the candidate tumor suppressor gene ING1 in human head and neck tumors with 13q deletions. Genes Chromosomes Cancer. 2000; 27(3):319-22. DOI: 10.1002/(sici)1098-2264(200003)27:3<319::aid-gcc13>3.0.co;2-p. View

Deng C, Zhang P, Harper J, Elledge S, Leder P . Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995; 82(4):675-84. DOI: 10.1016/0092-8674(95)90039-x. View

Turovets N, Agapova L, Kopnin P, Tulina N, Chumakov P, Kopnin B . [Effect of inactivating the p33ING1 tumor suppressor on the function of cell cycle "checkpoints" and genome stability]. Genetika. 2000; 36(3):385-92. View

Tokunaga E, Maehara Y, Oki E, Kitamura K, Kakeji Y, Ohno S . Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. Cancer Lett. 2000; 152(1):15-22. DOI: 10.1016/s0304-3835(99)00434-6. View

10.

Zeremski M, Horrigan S, Grigorian I, Westbrook C, Gudkov A . Localization of the candidate tumor suppressor gene ING1 to human chromosome 13q34. Somat Cell Mol Genet. 1997; 23(3):233-6. DOI: 10.1007/BF02721376. View

11.

Krishnamurthy J, Kannan K, Feng J, Mohanprasad B, Tsuchida N, Shanmugam G . Mutational analysis of the candidate tumor suppressor gene ING1 in Indian oral squamous cell carcinoma. Oral Oncol. 2001; 37(3):222-4. DOI: 10.1016/s1368-8375(00)00081-6. View

12.

Helbing C, Veillette C, Riabowol K, Johnston R, Garkavtsev I . A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res. 1997; 57(7):1255-8. View

13.

Scott M, Boisvert F, Vieyra D, Johnston R, Bazett-Jones D, Riabowol K . UV induces nucleolar translocation of ING1 through two distinct nucleolar targeting sequences. Nucleic Acids Res. 2001; 29(10):2052-8. PMC: 55466. DOI: 10.1093/nar/29.10.2052. View

14.

Morgan Jr R, Doroshow J, Venkataraman K, Chang K, Raschko J, Somlo G . High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support. Clin Cancer Res. 1998; 3(12 Pt 1):2337-45. View

15.

Steele R, Thompson A, Hall P, Lane D . The p53 tumour suppressor gene. Br J Surg. 1998; 85(11):1460-7. DOI: 10.1046/j.1365-2168.1998.00910.x. View

16.

Garkavtsev I . Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet. 1999; 23(3):373. DOI: 10.1038/15566. View

17.

Lodge A, Hall A, Reid M, McIntosh G, Steward M, Anderson J . Topoisomerase II alpha and II beta expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome. J Clin Pathol. 2001; 54(1):31-6. PMC: 1731267. DOI: 10.1136/jcp.54.1.31. View

18.

Garkavtsev I, Kazarov A, Gudkov A, Riabowol K . Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet. 1996; 14(4):415-20. DOI: 10.1038/ng1296-415. View

19.

Matsuo Y, Sugimoto A, Harashima A, Nishizaki C, Drexler H, Orita K . Myeloperoxidase positive acute lymphoblastic leukemia cell lines, NALM-30, NALM-31 and NALM-32, carrying Philadelphia chromosome with biphenotypic characteristics. Hum Cell. 1999; 11(4):221-30. View

20.

Detre S, Saclani Jotti G, Dowsett M . A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995; 48(9):876-8. PMC: 502883. DOI: 10.1136/jcp.48.9.876. View